雷珠单抗联合脉冲激光治疗慢性CSC合并PCV的临床疗效观察  

Clinical efficacy of leizumab combined with pulsed laser in treatment of chronic central serous chorioretinopathy complicated with polypoid choroidal vasculopathy

作　　者：顾晖晖 浦利军 黄爱萍 陆培荣[2] Gu Huihui;Pu Lijun;Huang Aiping;Lu Peirong(Zhangjiagang Hospital Affiliated to Suzhou Univercity,Suzhou 215600,China)

机构地区：[1]苏州大学附属张家港医院(张家港市第一人民医院)眼科,江苏苏州215600 [2]苏州大学附属第一人民医院眼科

出　　处：《海军医学杂志》2023年第3期275-278,共4页Journal of Navy Medicine

基　　金：张家港市科技支撑计划项目(ZKS1832)。

摘　　要：目的探究雷珠单抗联合脉冲激光治疗慢性中心性浆液性脉络视网膜病变(CSC)合并息肉状脉络膜血管病变(PCV)的临床疗效。方法选取2019年1月至2022年1月苏州大学附属张家港医院及苏州大学附属第一人民医院接诊的120例慢性CSC合并PCV患者的临床资料,根据治疗方式分为对照组(69只眼,雷珠单抗治疗)和观察组(51只眼,雷珠单抗联合微脉冲激光治疗)。统计2组患者治疗前后最佳矫正视力(BCVA)、中心视网膜厚度(CRT)、眼底渗点数目、临床疗效、不良反应与6个月内复发率。结果治疗后,2组logMAR BCVA、CRT、眼底渗点数均降低,且观察组logMAR BVCA、CRT、眼底渗点数低于对照组(P<0.05)。观察组的临床疗效优于对照组,复发率低于对照组(均P<0.05)。2组患者的不良反应发生率差异无统计学意义(P>0.05)。结论雷珠单抗联合脉冲激光治疗慢性CSC合并PCV的临床效果显著,可以有效提高患者视力,复发率低,安全性较高,可以在临床中推广使用。Objective To investigate the clinical efficacy of leizumab combined with pulsed laser in treatment of chronic central serous chorioretinopathy(CSC)complicated with polypoid choroidal vasculopathy(PCV).Methods The clinical data of 120 patients with chronic CSC combined with PCV admitted to Zhangjiagang Hospital Affiliated to Suzhou University and the First Affiliated Hospital of Suzhou University from January 2019 to January 2022 were selected as research subjects.The patients were divided into the control group(69 eyes,with ranibizumab treatment)and the observation group(51 eyes,with ranibizumab combined with micropulse laser treatment)according to different treatment methods.The best corrected visual acuity(BCVA),central retinal thickness(CRT),the number of fundus infiltration points,clinical efficacy,adverse reactions and recurrence rate within 6 months before and after treatment were analyzed statisticaly.Results After treatment,the logMAR,BCVA,CRT and the number of fundus exudation points in both groups decreased,and logMAR BVCA,CRT and the number of fundus infiltration points of the 2 groups decreased,with those of the observation group being lower than those of the control group(P<0.05).The clinical efficacy of the observation group was superior to that of the control group,and the recurrence rate of the former was lower than that of the latter(all P<0.05).There was no statistical significance in the incidence of adverse reactions,when comparisons were made between the two groups(P>0.05).Conclusion The Leizumab combined with pulsed laser in treatment of chronic CSC complicated with PCV could achieve significant clinical effects,improve patient vision,with low recurrence rate and good safety.For this reason,it is worth further clinic promotion.

关 键 词：雷珠单抗 脉冲激光 中心性浆液性脉络视网膜病变 息肉状脉络膜血管病变 最佳矫正视力 

分 类 号：R774[医药卫生—眼科]